Psychiatyr Clin Neurosci 58, 359-363, (2004). Satoh, F., Miyatake, R., Furukawa, A., & Suwaki, H View abstract in PubMed Post navigationPreviousPrevious post:Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumour and self-reliant cells and inhibit tumor growth in vitro and in vivo.NextNext post:Sigma-1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls.Related PostsAnavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett SyndromeJuly 1, 2020Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialJune 16, 2020Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)May 21, 2020
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)July 6, 2020
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett SyndromeJuly 1, 2020
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialJune 16, 2020
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)May 21, 2020
